Tags

Type your tag names separated by a space and hit enter

Aripiprazole in children and adolescents with Tourette disorder with and without explosive outbursts.
J Child Adolesc Psychopharmacol. 2008 Oct; 18(5):509-15.JC

Abstract

OBJECTIVE

We conducted a retrospective, observational study of aripiprazole for the treatment of tics and/or co-morbid explosive outbursts in 37 children and adolescents with Tourette disorder (TD).

METHOD

Thirty seven children and adolescents with TD, with and without explosive outbursts, and refractory to previous treatment were treated at one of two university affiliated specialty clinics. All diagnoses were made using Diagnostic and Statistical Manual of Mental Disorders, 4th edition, Text Revision (DSM-IV-TR) criteria. Tic severity was rated using the Clinical Global Impressions Scale for tics (CGI-Tics) and frequency of explosive outbursts was assessed using the CGI-Rage; both measures were obtained at pretreatment baseline and at posttreatment follow up.

RESULTS

High rates of psychiatric co-morbidity were observed in these subjects: 31 of 37 (84%) subjects met criteria for obsessive-compulsive disorder (OCD), and 31 of 37 (84%) met criteria for attention-deficit/hyperactivity disorder (ADHD). Twenty nine of 37 (78%) subjects met criteria for intermittent explosive disorder (IED) minus criterion C; the remaining 8 subjects had TD only. Eight subjects (22%) discontinued treatment before 12 weeks due to inability to tolerate the drug. At follow up, tics reduced at a mean daily dose of 12.3 (7.50) mg in 29 of 29 (100%) subjects who completed the study, and explosive outbursts improved in 24/25 subjects (96%) who completed the study. Aripiprazole was tolerated reasonably well, although 8/37 (22%) subjects discontinued treatment; most common side effects included weight gain, akathisia, and sedation.

CONCLUSION

Aripiprazole should be investigated further as a treatment option for TD with and without co-morbid explosive outbursts.

Authors+Show Affiliations

North Shore University Hospital-Long Island Jewish Hospital System, Manhasset, New York.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

18928415

Citation

Budman, Cathy, et al. "Aripiprazole in Children and Adolescents With Tourette Disorder With and Without Explosive Outbursts." Journal of Child and Adolescent Psychopharmacology, vol. 18, no. 5, 2008, pp. 509-15.
Budman C, Coffey BJ, Shechter R, et al. Aripiprazole in children and adolescents with Tourette disorder with and without explosive outbursts. J Child Adolesc Psychopharmacol. 2008;18(5):509-15.
Budman, C., Coffey, B. J., Shechter, R., Schrock, M., Wieland, N., Spirgel, A., & Simon, E. (2008). Aripiprazole in children and adolescents with Tourette disorder with and without explosive outbursts. Journal of Child and Adolescent Psychopharmacology, 18(5), 509-15. https://doi.org/10.1089/cap.2007.061
Budman C, et al. Aripiprazole in Children and Adolescents With Tourette Disorder With and Without Explosive Outbursts. J Child Adolesc Psychopharmacol. 2008;18(5):509-15. PubMed PMID: 18928415.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Aripiprazole in children and adolescents with Tourette disorder with and without explosive outbursts. AU - Budman,Cathy, AU - Coffey,Barbara J, AU - Shechter,Rachel, AU - Schrock,Matthew, AU - Wieland,Natalie, AU - Spirgel,Arie, AU - Simon,Elizabeth, PY - 2008/10/22/pubmed PY - 2009/2/3/medline PY - 2008/10/22/entrez SP - 509 EP - 15 JF - Journal of child and adolescent psychopharmacology JO - J Child Adolesc Psychopharmacol VL - 18 IS - 5 N2 - OBJECTIVE: We conducted a retrospective, observational study of aripiprazole for the treatment of tics and/or co-morbid explosive outbursts in 37 children and adolescents with Tourette disorder (TD). METHOD: Thirty seven children and adolescents with TD, with and without explosive outbursts, and refractory to previous treatment were treated at one of two university affiliated specialty clinics. All diagnoses were made using Diagnostic and Statistical Manual of Mental Disorders, 4th edition, Text Revision (DSM-IV-TR) criteria. Tic severity was rated using the Clinical Global Impressions Scale for tics (CGI-Tics) and frequency of explosive outbursts was assessed using the CGI-Rage; both measures were obtained at pretreatment baseline and at posttreatment follow up. RESULTS: High rates of psychiatric co-morbidity were observed in these subjects: 31 of 37 (84%) subjects met criteria for obsessive-compulsive disorder (OCD), and 31 of 37 (84%) met criteria for attention-deficit/hyperactivity disorder (ADHD). Twenty nine of 37 (78%) subjects met criteria for intermittent explosive disorder (IED) minus criterion C; the remaining 8 subjects had TD only. Eight subjects (22%) discontinued treatment before 12 weeks due to inability to tolerate the drug. At follow up, tics reduced at a mean daily dose of 12.3 (7.50) mg in 29 of 29 (100%) subjects who completed the study, and explosive outbursts improved in 24/25 subjects (96%) who completed the study. Aripiprazole was tolerated reasonably well, although 8/37 (22%) subjects discontinued treatment; most common side effects included weight gain, akathisia, and sedation. CONCLUSION: Aripiprazole should be investigated further as a treatment option for TD with and without co-morbid explosive outbursts. SN - 1557-8992 UR - https://www.unboundmedicine.com/medline/citation/18928415/Aripiprazole_in_children_and_adolescents_with_Tourette_disorder_with_and_without_explosive_outbursts_ L2 - https://www.liebertpub.com/doi/full/10.1089/cap.2007.061?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -